Evidence map›Paper›PMID 34905589›Full record

ArticlePloS one2021

Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations.

Ho Jae Lim, Min Young Park, Hye Soo Jung, Youngjin Kwon, Inhee Kim, Dong Kwan Kim, Nae Yu, Nackmoon Sung, Sun-Hwa Lee, Jung Eun Park and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Enhancing the epidemiological surveillance of SARS-CoV-2 using Sanger sequencing to identify circulating variants and recombinants.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ho Jae LimDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.ORCID 0000-0003-0115-5170
Min Young ParkDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Hye Soo JungDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Youngjin KwonDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Inhee KimDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Dong Kwan KimDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Nae YuDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Nackmoon SungClinical Research Institute, Seegene Medical Foundation, Seoul, Republic of Korea.
Sun-Hwa LeeDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.
Jung Eun ParkDepartment of Integrative Biological Sciences & BK21 FOUR Educational Research Group for Age-associated Disorder Control Technology, Chosun University, Gwangju, Republic of Korea.
Yong-Jin YangDepartment of Molecular Diagnostics, Seegene Medical Foundation, Seoul, Republic of Korea.ORCID 0000-0002-6153-9646
Chosun University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) harboring nucleotide changes (mutations) in the spike gene have emerged and are spreading rapidly. These mutations are associated with SARS-CoV-2 transmissibility, virulence, or resistance to some neutralizing antibodies. Thus, the accurate detection of spike mutants is crucial for controlling SARS-CoV-2 transmission and identifying neutralizing antibody-resistance caused by amino acid changes in the receptor-binding domain. Here, we developed five SARS-CoV-2 spike gene primer pairs (5-SSG primer assay; 69S, 144S, 417S, 484S, and 570S) and verified their ability to detect nine key spike mutations (ΔH69/V70, T95I, G142D, ΔY144, K417T/N, L452R, E484K/Q, N501Y, and H655Y) using a Sanger sequencing-based assay. The 5-SSG primer assay showed 100% specificity and a conservative limit of detection with a median tissue culture infective dose (TCID50) values of 1.4 × 102 TCID50/mL. The accuracy of the 5-SSG primer assay was confirmed by next generation sequencing. The results of these two approaches showed 100% consistency. Taken together, the ability of the 5-SSG primer assay to accurately detect key SARS-CoV-2 spike mutants is reliable. Thus, it is a useful tool for detecting SARS-CoV-2 spike gene mutants in a clinical setting, thereby helping to improve the management of patients with COVID-19.

Indexed as

MutationDNA PrimersHigh-Throughput Nucleotide SequencingHumansLimit of DetectionProtein DomainsSARS-CoV-2Sequence Analysis, RNASpike Glycoprotein, CoronavirusDNA PrimersSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID34905589
PMCPMC8670694
OpenAlexW4200388284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.